GMDP |
|
Vaxjo ID |
53 |
|
Vaccine Adjuvant Name |
GMDP |
|
Alternative Names |
N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (CAS Registry Number 70280-03-4) |
|
Adjuvant VO ID |
VO_0001295
|
|
Description |
GMDP is a highly effective primary adjuvant in a range of vehicles; aqueous buffers, mineral oil, pluronic/squalane/Tween emulsions. Also effective as oral adjuvant, enhancing mucosal IgA response (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Components |
N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (CAS Registry Number 70280-03-4); Disaccharide isolated from microbial origin, dipeptide wholly synthetic(Vogel and Powell, 1995). |
|
Molecular Weight |
695 |
|
Appearance |
White lyophilized powder. |
|
Storage |
Extremely stable at room temperature under dry conditions. For prolonged storage, desiccator at 4° C is recommended (Vogel and Powell, 1995). |
|
Safety |
Extensive Phase I systemic safety data in humans (mostly after oral administration). Single oral doses of up to 50 mg given with no side effects. Intramuscular injections of 1 mg given with minimal local reaction. LD50 in mouse = 7 gm/kg. Less pyrogenic than prototype muramyl dipeptide (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
